In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 3.3 above Maia Biotechnology Inc average.

Within Major Pharmaceutical Preparations industry 196 other companies have achieved higher Quick Ratio than Maia Biotechnology Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 660 to 761.

Explain Quick Ratio?
How much Cash & cash equivalents MAIA�s has?
What are MAIA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MAIA/financial-strength

https://api.csimarket.com/api/v1/companies/MAIA/fundamentals

https://api.csimarket.com/api/v1/companies/MAIA/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

MAIA Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-35.22 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	95.92 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	3.3	Subscribe	Subscribe	Subscribe	Subscribe
MAIA's Total Ranking	# 761	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	3.45 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-22.67 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 197
Healthcare Sector	# 325
Overall Market	# 761

Quick Ratio Statistics
High	Average	Low
5.73	2.7	1.09
(Sep 30 2022)		(Sep 30 2025)

Financial Statements
Maia Biotechnology Inc 's Current Liabilities	$ 6 Millions	Visit MAIA's Balance sheet
Maia Biotechnology Inc 's Cash & cash equivalent	$ 21 Millions	Visit MAIA's Balance sheet
Source of MAIA's Sales		Visit MAIA's Sales by Geography

Cumulative Maia Biotechnology Inc 's Quick Ratio

MAIA's Quick Ratio for the trailling 12 Months

MAIA Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	4.03 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	121.7 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	3.7	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 648	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-12.39 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	12.81 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to MAIA Financial Strength Comparisons >> Go to Compare MAIA Quick Ratio to its Competitors

On the trailing twelve months basis MAIA Cash & cash equivalent soared by 95.92 % in Q3 2026 year on year, while Current Liabilities rose to $6 millions, this led to increase in in Maia Biotechnology Inc 's Quick Ratio to 3.7, above MAIA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 428 other companies have achieved higher Quick Ratio than Maia Biotechnology Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3832 to 3843.

Explain Quick Ratio?
How much Cash & cash equivalents MAIA�s has?
What are MAIA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 429
Healthcare Sector	# 873
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
3.27	2.35	1.56
(Jun 30 2023)		(Dec 31 2025)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Opus Genetics Inc	9.05	$ 88.974 Millions	$ 9.832 Millions
Ibio inc	8.94	$ 76.654 Millions	$ 8.574 Millions
Ideaya Biosciences Inc	8.70	$ 838.541 Millions	$ 96.405 Millions
First Tracks Biotherapeutics Inc	8.60	$ 155.627 Millions	$ 18.090 Millions
Pepgen Inc	8.48	$ 104.805 Millions	$ 12.361 Millions
Medicinova Inc	8.47	$ 29.256 Millions	$ 3.456 Millions
Polaryx Therapeutics Inc	8.45	$ 8.440 Millions	$ 0.999 Millions
Ocular Therapeutix Inc	8.42	$ 530.612 Millions	$ 63.017 Millions
Evommune Inc	8.25	$ 169.033 Millions	$ 20.483 Millions
Arvinas Inc	7.98	$ 558.400 Millions	$ 70.000 Millions
Pliant Therapeutics Inc	7.90	$ 141.614 Millions	$ 17.921 Millions
Wave Life Sciences Ltd	7.87	$ 431.012 Millions	$ 54.760 Millions
Savara Inc	7.80	$ 129.649 Millions	$ 16.630 Millions
Rigel Pharmaceuticals Inc	7.79	$ 224.456 Millions	$ 28.806 Millions
Cytomx Therapeutics Inc	7.64	$ 347.980 Millions	$ 45.532 Millions
Atea Pharmaceuticals Inc	7.64	$ 191.199 Millions	$ 25.025 Millions
Braveheart Bio, Inc.	7.27	$ 121.291 Millions	$ 16.673 Millions
Viking Therapeutics Inc	7.17	$ 959.813 Millions	$ 133.897 Millions
Scynexis Inc	7.09	$ 47.165 Millions	$ 6.652 Millions
Lb Pharmaceuticals Inc	7.03	$ 215.075 Millions	$ 30.573 Millions
Zentalis Pharmaceuticals Inc	7.03	$ 228.893 Millions	$ 32.539 Millions
Quoin Pharmaceuticals Ltd	6.95	$ 33.184 Millions	$ 4.776 Millions
Vera Therapeutics Inc	6.89	$ 384.042 Millions	$ 55.775 Millions
Nuvation Bio Inc	6.73	$ 663.370 Millions	$ 98.559 Millions
Ensysce Biosciences Inc	6.71	$ 29.671 Millions	$ 4.419 Millions
Anaptysbio Inc	6.71	$ 230.319 Millions	$ 34.318 Millions
Coya Therapeutics Inc	6.64	$ 35.802 Millions	$ 5.395 Millions
Capricor Therapeutics inc	6.61	$ 197.581 Millions	$ 29.895 Millions
Arcturus Therapeutics Holdings Inc	6.52	$ 184.817 Millions	$ 28.345 Millions
Moonlake Immunotherapeutics	6.50	$ 379.704 Millions	$ 58.430 Millions

Date modified: 2026-11-10T06:21:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.